Merck signs agreement to buy Acceleron Pharma for $11.5bn

The deal will help Merck gain access to Acceleron’s lead therapeutic candidate, sotatercept. Credit: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A. All rights reserved.